000310292 001__ 310292
000310292 005__ 20260305150900.0
000310292 0247_ $$2doi$$a10.1016/j.canlet.2026.218389
000310292 0247_ $$2pmid$$apmid:41780845
000310292 0247_ $$2ISSN$$a0304-3835
000310292 0247_ $$2ISSN$$a1872-7980
000310292 037__ $$aDKFZ-2026-00515
000310292 041__ $$aEnglish
000310292 082__ $$a570
000310292 1001_ $$0P:(DE-HGF)0$$aCidre-Aranaz, Florencia$$b0$$eFirst author
000310292 245__ $$acIAP1 inhibitor of apoptosis is a tumor suppressor in Ewing sarcoma.
000310292 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2026
000310292 3367_ $$2DRIVER$$aarticle
000310292 3367_ $$2DataCite$$aOutput Types/Journal article
000310292 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1772719728_1921028
000310292 3367_ $$2BibTeX$$aARTICLE
000310292 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000310292 3367_ $$00$$2EndNote$$aJournal Article
000310292 500__ $$a#EA:B410#LA:B410# / epub
000310292 520__ $$aEwing sarcoma (EwS) is a highly aggressive pediatric malignancy driven by EWSR1::ETS fusion oncoproteins -primarily EWSR1::FLI1- which deregulate genes essential for differentiation, proliferation, and cell survival. To uncover key downstream targets of this fusion involved in cell differentiation, we combined transcriptomic profiling of EwS cell lines following EWSR1::FLI1 inhibition with gene ontology analysis, a clinically annotated gene expression dataset derived from EwS patient material and network analyses. This integrative approach identified inhibitor of apoptosis protein 1 (cIAP1, alias BIRC2) as an EWSR1::FLI1-suppressed gene. Despite its known oncogenic role in many cancers, cIAP1 showed minimal expression in EwS. Using inducible cIAP1 re-expression models in EwS cells, we demonstrated that cIAP1 re-expression suppresses proliferation, clonogenic growth, and 3D spheroid formation in vitro. Transcriptomic and proteomic analyses revealed that low cIAP1 expression enhances proliferation-related gene signatures, which are inhibited upon cIAP1 re-expression. In vivo xenograft models revealed that cIAP1 re-expression significantly reduces tumor growth, mitotic activity, and Ki-67 positivity, while increasing tumor necrosis and apoptosis. These findings highlight an unexpected tumor-suppressive role for cIAP1 in fusion-driven sarcomas, contrasting with its pro-survival function in other cancers. Collectively, our results identify cIAP1 as a prognostically relevant, EWSR1::FLI1-regulated hub whose re-expression disrupts tumor progression, offering a potential therapeutic strategy to restore tumor-suppressive pathways in EwS.
000310292 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000310292 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000310292 650_7 $$2Other$$aBIRC2
000310292 650_7 $$2Other$$aEwing sarcoma
000310292 650_7 $$2Other$$aapoptosis
000310292 650_7 $$2Other$$acIAP1
000310292 650_7 $$2Other$$apediatric sarcoma
000310292 7001_ $$0P:(DE-He78)824510670ec489266e6e294c4f8b0e6c$$aGeyer, Florian H$$b1$$udkfz
000310292 7001_ $$0P:(DE-He78)950b74cdfed452da91ceefd57d110764$$aHölting, Tilman$$b2
000310292 7001_ $$0P:(DE-He78)10e529acefa6ce98a57e02e2fddab48f$$aHanssen, Kimberley M$$b3$$udkfz
000310292 7001_ $$0P:(DE-He78)40245f2168b87c014e445cabf610fd46$$aFaehling, Tobias$$b4$$udkfz
000310292 7001_ $$0P:(DE-He78)92c7abef8ab1c49cda71bfafccee3fdb$$aRitter, Alina$$b5$$udkfz
000310292 7001_ $$0P:(DE-He78)8746c92b0303748b84d9cf25912aa9fd$$aZimmermann, Malenka$$b6$$udkfz
000310292 7001_ $$0P:(DE-He78)507c97fafa917642c6757c53a3ca3383$$aMao, Lianghao$$b7$$udkfz
000310292 7001_ $$aAlonso, Javier$$b8
000310292 7001_ $$aSastre, Ana$$b9
000310292 7001_ $$0P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af$$aJayavelu, Ashok Kumar$$b10$$udkfz
000310292 7001_ $$0P:(DE-He78)ddba8e300cae44b1021c9b65192fdb36$$aKnott, Maximilian M L$$b11$$udkfz
000310292 7001_ $$0P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41$$aMusa, Julian$$b12$$udkfz
000310292 7001_ $$0P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aGrünewald, Thomas$$b13$$eLast author$$udkfz
000310292 773__ $$0PERI:(DE-600)2004212-7$$a10.1016/j.canlet.2026.218389$$gp. 218389 -$$pnn$$tCancer letters$$vnn$$x0304-3835$$y2026
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)824510670ec489266e6e294c4f8b0e6c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)950b74cdfed452da91ceefd57d110764$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)10e529acefa6ce98a57e02e2fddab48f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)40245f2168b87c014e445cabf610fd46$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92c7abef8ab1c49cda71bfafccee3fdb$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8746c92b0303748b84d9cf25912aa9fd$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)507c97fafa917642c6757c53a3ca3383$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ddba8e300cae44b1021c9b65192fdb36$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)476ba475ebb0d48ae4ec27f03d836a41$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000310292 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a590ab95c6f7ba52880452da78ecd6c$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000310292 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000310292 9141_ $$y2026
000310292 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-12$$wger
000310292 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER LETT : 2022$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-12
000310292 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER LETT : 2022$$d2025-11-12
000310292 9202_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000310292 9201_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000310292 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000310292 9201_ $$0I:(DE-He78)A400-20160331$$kA400$$lKKE Pädiatrische Leukämie$$x2
000310292 9200_ $$0I:(DE-He78)B410-20160331$$kB410$$lTranslationale Pädiatrische Sarkomforschung$$x0
000310292 980__ $$ajournal
000310292 980__ $$aVDB
000310292 980__ $$aI:(DE-He78)B410-20160331
000310292 980__ $$aI:(DE-He78)HD01-20160331
000310292 980__ $$aI:(DE-He78)A400-20160331
000310292 980__ $$aUNRESTRICTED